We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
- Authors
Elin Lindhagen; Linda Rickardson; Gary Elliott; Lorenzo Leoni; Peter Nygren; Rolf Larsson; Anna Åleskog
- Abstract
Summary SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their cytotoxic activity was further studied herein using a well-characterized human tumour cell-line panel containing ten cell lines, as well as in 58 primary tumour cell samples from a variety of diagnoses. The indole-pyran analogues of SDX-101 were in general considerably more active in both cancer cell lines and primary tumour samples. Low cross-reactivity with standard agents was observed, indicating a unique mechanism of action. No apparent influence on efficacy was observed via classical mechanisms of multidrug-resistance. SDX-101 and SDX-309 showed higher relative activity in haematological compared to solid tumour samples, while SDX-308 had pronounced solid-tumour activity. High SDX-308 cytotoxic efficacy was observed in non-small cell lung cancer, renal cancer and ovarian cancer samples, and also in chronic lymphocytic leukaemia. In conclusion, the indole-pyran analogues showed a favourable pharmacological profile and represent a potentially important new class of drugs for cancer treatment.
- Subjects
NONSTEROIDAL anti-inflammatory agents; TUMOR treatment; CANCER cells; CLINICAL medicine
- Publication
Investigational New Drugs, 2007, Vol 25, Issue 4, p297
- ISSN
0167-6997
- Publication type
Article
- DOI
10.1007/s10637-007-9049-4